RNA, U6 small nuclear 606, pseudogeneGenealiases: []
Q-omics provides the consensus-scored RNU6-606P profile across patient tissues and cancer cell-line models. RNU6-606P expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, RNU6-606P is differentially expressed in 3, with the highest sampling consensus in LUSC. Additionally, RNU6-606P RNA expression shows 7,012 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight LUSC, and LUAD as cancer lineages where RNU6-606P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU6-606P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU6-606P survival associations across molecular data types. RNU6-606P RNA expression shows survival associations in the most cancer types (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU6-606P RNA expression–survival associations across cancer types. High RNU6-606P expression shows unfavorable associations in LUSC, LIHC, LGG and PAAD, but favorable associations in LUAD and SKCM. The LUSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUSC as the clearest survival context for RNU6-606P RNA expression.
This table summarizes RNU6-606P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for RNU6-606P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU6-606P shows lower tumor expression in LUSC and THCA and higher tumor expression in KICH. The LUSC box plot shows higher RNU6-606P RNA expression in normal versus tumor tissue (log2 FC = −0.329, t-test p = .005).
This table shows molecular features associated with RNU6-606P in patient tissues and cancer cell lines. In patient samples, RNU6-606P shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set.
